-
AptaBLE: Deep Learning for Aptamer Design
2026-09-19
AptaBLE combines pretrained protein and nucleic acid sequence encoders with symmetric bidirectional cross-attention to predict aptamer–protein binding and support de novo aptamer generation. The preprint reports improved predictive performance and generated candidates with reported affinities as low as 31 nM, while emphasizing the need for experimental validation.
-
mCherry mRNA as a Delivery-System Readout
2026-09-18
Discover how mCherry mRNA can function as more than a fluorescent reporter: it can reveal whether an mRNA delivery system successfully achieves cytosolic release and translation. This article connects Cap 1 design, modified nucleotides, and LNP assay strategy to findings from disease-relevant fibroblast research.
-
Imidazoline Antagonists and β-Cell K+ Channels
2026-09-18
This study showed that imidazoline α2-adrenoceptor antagonists increase insulin release primarily by inhibiting ATP-sensitive K+ channels in pancreatic β-cells, rather than solely by blocking α2 receptors. Its combination of 86Rb efflux, insulin-release, and patch-clamp experiments provides a useful framework for interpreting Tolazoline in islet function research.
-
Y-27632 Dihydrochloride in Cell Adhesion
2026-09-17
Y-27632 dihydrochloride offers a precise way to interrogate ROCK-dependent cytoskeletal remodeling in pluripotent stem cell adhesion assays. This article connects ROCK biology with a recent interspecies chimerism study, showing how to separate survival, junction formation, and genuine adhesion effects.
-
Bazedoxifene and IL-6/GP130 Signaling in Cancer
2026-09-17
Shi and colleagues review bazedoxifene as a potential anticancer agent that interferes with IL-6/GP130 signaling, linking an established osteoporosis drug to a pathway that regulates tumor survival, proliferation, and therapy resistance. The paper synthesizes molecular, cellular, and combination-treatment evidence while emphasizing that clinical repositioning still requires biomarker-guided validation and standardized studies.
-
TNF-alpha Recombinant Murine Protein Workflow
2026-09-16
Build controlled apoptosis and inflammation assays with a defined murine cytokine rather than relying on complex biological mixtures. This workflow pairs TNF receptor stimulation with orthogonal measurements inspired by recent RNA Pol II cell-death research, helping distinguish receptor-driven signaling from transcriptional-loss mechanisms.
-
(-)-Arctigenin MEK1 Inhibitor Workflows
2026-09-15
Use (-)-Arctigenin as a reversible pathway probe to connect LPS–NF-κB signaling, MEK1 activity, and macrophage extracellular-vesicle models. This workflow emphasizes solvent control, time-resolved signaling, and orthogonal validation so an anti-inflammatory agent is not mistaken for a pathway-specific genetic perturbation.
-
Reelin–SFK Signaling Permits Ketamine Action
2026-09-15
The PNAS study shows that Reelin–Apoer2–Src family kinase signaling is a permissive requirement for ketamine-induced hippocampal plasticity and behavioral effects in mice. Its key contribution is distinguishing maintenance of baseline NMDA receptor function from acute ketamine-driven pathway activation, offering a mechanistic framework for incomplete antidepressant response.
-
Biotin-16-UTP: Translating RNA Labels into Insight
2026-09-14
Biotin-16-UTP connects mechanistically informed RNA labeling with practical translational strategy. This thought-leadership article explains how affinity-tagged transcripts support RNA detection, purification, interaction studies, and localization workflows, while positioning recent endogenous-protein biosensor research as a complementary model for building more faithful biological evidence.
-
Calnexin-Dependent Rescue of CFTR Variants
2026-09-14
Tedman et al. use deep mutational scanning to show that calnexin is a variant-dependent determinant of CFTR surface expression and corrector responsiveness across a broad clinical variant set. The study separates proteostasis effects from channel activity, offering a framework for interpreting why F508del CFTR correctors and related modulators perform differently across genotypes.
-
LY2228820: A p38 MAPK Assay-to-Application Guide
2026-09-13
Explore how LY2228820, a selective p38 MAP kinase inhibitor, connects target engagement with inflammation, angiogenesis, and tumor-cell phenotypes. This guide translates pathway evidence into a practical, evidence-aware assay strategy inspired by airway restenosis research.
-
FAISL–FAK Signaling in Triple-Negative Breast Cancer
2026-09-12
The reference study identifies FAISL as a long noncoding RNA that stabilizes focal adhesion kinase by shielding it from Calpain 2-mediated proteolysis. Its integrated transcriptomic, biochemical, cellular, and mouse-model evidence connects this mechanism to TNBC adhesion, survival, growth, and metastasis, while also supporting FAISL-directed RNA delivery as a research avenue.
-
JXY Reprograms Macrophages in Colitis-Associated CRC
2026-09-12
The reference study shows that Jiedu Xiaozheng Yin limits colitis-associated colorectal cancer in mice while shifting intestinal macrophages toward an M1-like state through TLR4-associated signaling. Its combination of tumor phenotyping, macrophage functional assays, transcriptional readouts, and pathway antagonism provides a useful framework for studying inflammation-driven tumor progression.
-
Stat3 in Fyn-Driven Dopaminergic Neurodegeneration
2026-09-11
This zebrafish study identifies Stat3 as a downstream effector linking constitutively active Fyn kinase to dopaminergic neuron loss, mitochondrial abnormalities, and microglia-associated inflammation. Its combination of cell-type-specific genetics, live imaging, transcriptomics, and pathway inhibition provides a mechanistic framework for studying neurodegeneration and designing future functional gene studies.
-
TUNEL Signals in the Pyroptosis Era
2026-09-11
A translational guide to interpreting TUNEL signals alongside pyroptosis biology, with practical strategies for tissue, cell-based, and combination-therapy studies.